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Abstract: Protein kinases have emerged as crucial targets for cancer therapy over the last decades.
Since 2001, 40 and 39 kinase inhibitors have been approved by FDA and EMA, respectively, and
the majority are antineoplastic drugs. Morevoer, many candidates are currently in clinical trials.
We previously reported a small library of 4-aminoimidazole and 2-aminothiazole derivatives active as
Src family kinase (SFK) inhibitors. Starting from these results, we decided to perform an optimization
study applying a mix and match strategy to identify a more potent generation of 4-aminoimidazoles.
Firstly, a computational study has been performed, then compounds showing the best predicted
docking scores were synthesized and screened in a cell-free assay for their SFK inhibitory activity.
All the new chemical entities showed IC50s in the nanomolar range, with 2–130 fold increased
activities compared to the previously reported inhibitors. Finally, the most active compounds have
been tested on three cancer cell lines characterized by Src hyperactivation. Compounds 4k and 4l
showed an interesting antiproliferative activity on SH-SY5Y neuroblastoma (NB) cell line. In this
assay, the compounds resulted more potent than dasatinib, a tyrosine kinase inhibitor approved for
the treatment of leukemias and in clinical trials for NB.
Keywords: aminoimidazole; SFK inhibitors; neuroblastoma; anticancer; tyrosine kinases
1. Introduction
Protein kinases are a large class of enzymes (to date 518 members have been identified) which are
involved in different phases of the cell life [1]. These proteins are overexpressed and/or hyperactivated
in several diseases, including cancer, neurodegenerative disorders and inflammation [2]. For this
reason, protein kinases have become a thoroughly studied target in medicinal chemistry and, to date,
40 and 39 kinase inhibitors have been approved by the FDA and EMA, respectively, and the majority
are antineoplastic drugs [3].
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Protein kinases phosphorylate tyrosine, serine, and threonine residues in protein substrates and on
this basis are classified as tyrosine kinases (TKs) and serine/threonine kinases (STKs) [4]. Human TKs
are further divided in two main families: receptor tyrosine kinases and non-receptor tyrosine kinases.
Into the latter, Src family kinases (SFKs) are the biggest subfamily of enzymes. This class includes
nine highly homologous members, i.e., Src, Fyn, Yes, Blk, Yrk, Fgr, Hck, Lck, and Lyn. All SFKs
present a common structure characterized by a N-terminal Src homology domain (SH4), a ‘unique’
region—different among SFK members, two Src homology domains (SH2 and SH3), a catalytic domain
(SH1), and a short C-terminal tail. The catalytic domain constitutes the core of the enzyme since it
possesses the kinase activity. SH1 presents a bilobal structure, with a small N-terminal lobe and a
large C-terminal lobe, linked by a flexible chain, named hinge region [5]. At the interlobe cleft there
are the ATP- and substrate-binding sites. Under basal conditions, SFKs present a close and inactive
conformation that prevents ATP and substrate binding. After phosphorylation of a specific tyrosine
residue (Tyr419 in human Src) in the C-terminal lobe by upstream kinases, a structural rearrangement
occurs and results in a flip to an open and active conformation. At this point, the enzyme is able to
bind ATP and the opportune peptide substrate, that will be phosphorylated [6,7]. SFKs are involved in
the regulation of different signal transduction pathways such as growth, proliferation, differentiation,
migration, metabolism, and apoptosis and, as reported for kinases in general, their overexpression
and/or hyperactivation have been shown in many types of tumors [8,9]. Interestingly, despite the
high homology among SFK members, different pathological implications have been detected inside
the family. For instance, Fyn plays a key role in brain pathologies, such as Alzheimer’s disease [10],
whereas Hck, Fgr, and Lyn are the main SFK members involved in inflammation [11].
To date, three molecules active as SFK inhibitors have been approved for clinical use, i.e., dasatinib,
bosutinib, and ponatinib (Figure 1) [3,12,13]. Anyway, these compounds are not selective SFK
inhibitors, but also inhibit other kinases. Dasatinib (Sprycel®, Bristol-Myers Squibb, approved in 2006),
and bosutinib (Bosulif®, Wyeth, approved in 2012), are two dual Src/Bcr-Abl (another non-receptor
TK) inhibitors which bind the enzymes in their active conformation. Dasatinib potently inhibits
all nine members of SFKs [14] and, in detail, a KINOMEscan analysis published by Davis et al. in
2011 [15] showed that it possesses Kd values of 0.21, 0.30, 0.53, and 0.79 nM on c-Src, Yes, Lyn, and
Fyn, respectively. The compound also inhibits other TKs, including Kit, PDGFR, ephrin A receptor
kinase, and the Tec kinase Btk [16]. Dasatinib has been approved for the treatment of chronic myeloid
leukemia (CML) and acute lymphoblastic leukemia Philadelphia chromosome-positive (ALL Ph+),
and is currently in clinical trials for NB and other solid tumors [17]. NB is an extracranial solid
tumor of childhood often characterized by poor prognosis and for which an effective treatment still
lacks. Bosutinib has been approved for the treatment of CML Ph+ with resistance or intolerance to
prior therapy, and in December 2017, the FDA granted accelerated approval as first line therapy [18].
Ponatinib (Iclusig®, Ariad Pharmaceuticals, approved in 2012) is a so-called “pan-kinase” inhibitor,
since it is active against many kinases, including SFKs, Bcr-Abl, VEGFR, PDGFR, and Ret. Ponatinib
binds Src and Bcr-Abl in their inactive conformation. It has been approved for CML or ALL Ph+,
in particular for resistant T315I-positive CML or T315I-positive, Ph+ ALL [19].
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Figure 1. Structures of approved SFK inhibitors dasatinib, bosutinib, and ponatinib. 
Although the majority of protein kinase inhibitors occupy the ATP binding site, few compounds 
are able to bind pockets that are far from the catalytic cleft and act as allosteric inhibitors [20]. The 
complexity in regulating kinases’ activity offers many potential routes for pursuing their inhibition 
Figure 1. Struct res of ap roved SFK i i it rs dasatinib, bosutinib, and po atinib.
Although the majority of protein kinase i rs o cupy the ATP binding site, few c mpounds
are abl to bind pockets that f r from the catalytic cleft nd act as allosteric inhibitors [20].
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The complexity in regulating kinases’ activity offers many potential routes for pursuing their inhibition
and, despite the initial concerns about the possibility to identify potent and selective kinases inhibitors,
significant advances have been made over the past two decades [21–23].
As widely reported in the literature, kinase inhibitors usually have heteroaromatic scaffolds
capable of interacting with the hinge region [8]. Therefore, the synthesis of new hinge interacting
moieties is crucial to obtain new molecules that may be selective for one or a few kinases and endowed
with a high inhibitory potency.
Zhang et al. described in detail the binding site of different kinase inhibitors and showed many
heterocyclic ring systems that occupy the purine binding site [24]. The strength of the binding between
these heterocyclic moieties and the target kinase is due to electrostatic interactions; in particular, some
hinge binders were designed to establish one to three hydrogen bonds to the hinge region.
From an extensive literature study, the 4-aminoimidazole and the 2-aminothiazole rings emerged
as interesting starting entities for the development of new ATP pocket binders. The 4-aminoimidazole
moiety has been first explored by AstraZeneca [25], who highlighted the ability of this scaffold to
bind the Janus kinase hinge region. The authors compared their clinical candidate AZD1480 (a Jak2
inhibitor with an IC50 of 58 nM, Figure 2), containing the 3-aminopyrazole moiety, with the related
4-aminoimidazole derivative (IC50 value of 120 nM towards Jak2), and found that this bioisosteric
substitution could be an effective replacement for the 3-aminopyrazole ring. The subsequent
modulation of this first hit led to the discovery of the potent and orally bioavailable Jak2 inhibitor 1
(IC50 < 3 nM, Figure 2) [25].
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Figure 2. Molecular structures of AZD1480, 1, and CGP77675. 
On the other hand, the 2-aminothiazole represents the hinge binder moiety of dasatinib, the 
potent SFK inhibitor already reported.  
In a previous work, we described the synthesis and the biological evaluation of a set of 4-
aminoimidazole and 2-aminothiazole derivatives as SFK inhibitors [26]. The 4-aminoimidazole ring 
was demonstrated to be an effective hinge binder for c-Src kinase, suggesting that this moiety, 
properly functionalized, is a good replacement for the aminothiazole ring [26]. Indeed, the most 
active compound 2 (Figure 3) showed IC50 values of 220, 689, 1300, and 167 nM for the isolated 
enzymes Src, Fyn, Lyn, and Yes, respectively (Table 1), and resulted active on SH-SY5Y 
neuroblastoma (NB) cell line with an IC50 of 25 μM. On the other hand, 2 showed a weak activity on 
K562 CML cell line, possessing an IC50 > 25 μM. As a continuation of our work, herein we present an 
optimization study aimed at obtaining a new generation of (1H-imidazol-4-yl)-pyrimidin-4-yl-
amines endowed with a higher affinity towards SFKs and a stronger activity on cells compared to 
compounds previously reported by us.  
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On the other hand, t e 2-aminothiaz le repr sents the hinge binder moiety of dasatinib, the potent
SFK inhibitor already reported.
In a previous work, we described the synthesis and the biological evaluation of a set of
4-aminoimidazole and 2-aminothiazole derivatives as SFK inhibitors [26]. The 4-aminoimidazole
ring was demonstrated to be an effective hinge binder for c-Src kinase, suggesting that this moiety,
properly functionalized, is a good replacement for the aminothiazole ring [26]. Indeed, the most active
compound 2 (Figure 3) showed IC50 values of 220, 689, 1300, and 167 nM for the isolated enzymes
Src, Fy , Lyn, nd Yes, respectively (T ble 1), and resulted active on SH-SY5Y neurobl stoma (NB)
cell line with an IC50 of 25 µM. On the other hand, 2 showed weak activity on K562 CML cell line,
possessing an IC50 > 25 µM. As a continuation of our wo k, herein we present an optimization study
aimed at obtaining a ne generation of (1H-imidazol-4-yl)-pyrimidin-4-yl-amines endowed with a
higher affinity towards SFKs and a stronger activity on cells compared to compounds previously
reported by us.
2. Results and Discussion
2.1. Docking Studies
Starting from our hit 2 [26] and 3 (a potent Src inhibitor) [27], a mix and match strategy combined
with the use of computational tools has been applied for the identification of new chemical entities
(NCEs) acting as ATP pocket binders (Figure 3). As a first step towards a better understanding of the
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molecular determinants for the inhibitory activity of this class of compounds against Src, a molecular
docking simulation has been performed on NCEs and the upcoming results were compared with
the best aminoimidazole hit 2 reported in our previous work [26]. In particular, more than one
hundred NCEs were designed and docked into the ATP binding site of Src by using the 3G5D X-ray
structure [28]. The mix and match strategy has been applied in order to (i) introduce different alkyl
groups as linkers to investigate the steric hindrance allowed around the hinge region; (ii) introduce
hydrophobic and hydrophilic moieties interacting with the hydrophobic region I (HRI) to improve the
primary activity by achieving electrostatic interactions that would be missing with an unsubstituted
phenyl group; (iii) replace the solvent exposed substituent with different types of heterocycles.
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Docking studies were performed by means of Glide [29] software and the reliability of the 
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Figure 3. The mix and match str t applied for the design of NCEs.
Docking studies were performed by means of Glide [29] software and the reliability of the applied
protocol was first assessed by reproducing the experimental binding mode of two known inhibitors of
Src: dasatinib (PDB code: 3G5D) [28] and CGP77675 (PDB code: 1YOL [30], Figure 2). Compounds
were drawn, minimized and finally docked into the ATP-binding site of Src (3G5D) [28].
As a result, the program was able to reproduce the experimental poses of the two compounds
with a RMSD of 0.55 Å suggesting that the docking procedure could be reliable to predict the binding
mode of our NCEs (Figure 4).
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Figure 4. Docking pose of CGP77675 (gray sticks) in the ATP-binding site of c-Src. The X-ray structure
has been overlapped for reference (magenta sticks). For sake of clarity, only a few residues are displayed
in gray sticks. Hydrogen bonds are shown as yellow dashes.
Compounds 4a–g (Table 1), showing the best predicted docking scores, are characterized by
a series of polar moieties in the solvent exposed region, and hydroxyl or methoxyl groups on the
phenyl ring of the N-1-(2-phenylethyl)-1H-imidazol-4-yl side chain. These substitution patterns
have been selected with the aim of improving the water solubility and getting further insights into
this class of inhibitors. All compounds showed a similar interaction pattern characterized by two
hydrogen bonds involving the imidazole nucleus and the hinge region: one between the N3 and the
NH backbone of Met341, and one between the 4-NH and the CO backbone of Met341. The phenyl
Molecules 2018, 23, 2369 5 of 17
ring was located into the HR1, forming Van der Waals interactions with hydrophobic amino acids of
this region. Moreover, the new N-[1-(2-phenylethyl)-1H-imidazol-4-yl]pyrimidinamines interacted
with two different residues in HR1 and in solvent exposed area. The best compounds in terms of
docking scores show a meta or ortho hydroxyl group on the phenyl ring and an amide, ester, or
carbamate group in N4 position of the piperazine chain. In detail, the pose example of compound 4j
(GB = −11.33 kcal/mol) has been reported in Figure 5: the meta hydroxyl group acts as both H-bond
donor and acceptor in the interactions with Glu310 and Asp464 respectively. The ortho substituted
derivative 4g (GB = −11.23 kcal/mol) establishes a hydrogen bond interaction with Asp464 belonging
to the DFG motif.
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Cmpd R1 R2 Src Docking Score (kcal/mol) 
Src IC50 
(nM) a 
Fyn IC50 
(nM) a 
Lyn IC50 
(nM) a 
Yes IC50 
(nM) a 
dasat.    <4 b <9 b <0.9 b <3 b 
2 H -C 2 2  −10.02 220 ±0.03 689 ± 0.10  1300 ± 0.02 167 ± 0.03 
4a -3OMe -C 2 H2OH −10.10 260 ± 23  146 ± 30 451 ± 13 560 ± 40 
4b -3OMe -C 2 ON 2 −7.26 1476 ± 185  1454 ± 768 1808 ± 307 1843 ± 812 
4c -2OMe -CH2CH2OH −10.58 225 ± 8 439 ± 45 145 ± 31 55 ± 9 
4d -2OMe -CH2CONH2 −8.33 1533 ± 44 1387 ± 93 1205 ± 189 NA 
4e -2OH -CH2CH2OH −10.97 59 ± 5 73 ± 5 17 ± 0.54 11 ± 0.6 
4f -2OH -H −10.98 56 ± 5 50 ± 4 51 ± 3 3 ± 1 
4g -2OH -CH2CONH2 −11.23 40 ± 5 40 ± 5 19 ± 2 15 ± 4 
Cmpd R1 R2
Src Docking Score
(kcal/mol)
Src IC50
(nM) a
Fyn IC50
(nM) a Lyn IC50 (nM)
a Yes IC50
(nM) a
dasat. <4 b <9 b <0.9 b <3 b
2 H -CH2CH2OH −10.02 220 ±0.03 689 ± 0.10 1300 ± 0.02 167 ± 0.03
4a -3OMe -CH2CH2OH −10.10 260 ± 23 146 ± 30 451 ± 13 560 ± 40
4b -3OMe -CH2CONH2 −7.26 1476 ± 185 1454 ± 768 1808 ± 307 1843 ± 812
4c -2OMe -CH2CH2OH −10.58 225 ± 8 439 ± 45 145 ± 31 55 ± 9
4d -2OMe -CH2CONH2 −8.33 1533 ± 44 1387 ± 93 1205 ± 189 NA
4e -2OH -CH2CH2OH −10.97 59 ± 5 73 ± 5 17 ± 0.54 11 ± 0.6
4f -2OH -H −10.98 56 ± 5 50 ± 4 51 ± 3 3 ± 1
4g -2OH -CH2CONH2 −11.23 40 ± 5 40 ± 5 19 ± 2 15 ± 4
4h -3OH -CH2C 2OH −10.80 93 ± 19 10 ± 0.4 20 ± 0.8 3 ± 1
4i -3OH -H −10.68 83 ± 18 10 ± 0.4 27 ± 1 3 ± 0.8
4j -3OH -CH2CONH2 −11.33 40 ± 3 12 ± 2 10 ± 1.2 3 ± 0.7
4k -3OH -CH2COOMe −10.99 40 ± 2 9 ± 1 18 ± 1 3 ± 1
4l -3OH -COOtert-butyl −10.99 50 ± 3 14 ± 1.5 26 ± 3 7 ± 0.35
a The compound was tested in two independent experiments, and IC50 values are the mean ± SD. b Dasatinb was
used as reference; the IC50 values of dasatinib were less than that of enzyme concentrations, which were 4, 9, 0.9,
and 3 nm for Src, Fyn, Lyn, and Yes, respectively.
As shown in Table 1, compounds 4g and 4j, having the highest values of docking score,
are predicted to be the most active compounds on the selected kinase, while compounds 4b and
4d (−7.266 and −8.336 kcal/mol respectively) resulted as the least active ones.
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2.2. Chemistry
The best predicted derivatives, in respect to our previous reported hit 2, were selected to
be synthesized and tested (Table 1). 4b and 4d were also prepared as negative controls in
enzymatic assays. Compounds 4a–d, bearing a hydrophobic group –OMe exposed to HR1, were first
synthesized (Scheme 1) [26]. The commercially available 4-nitro-1H-imidazole 5 was regioselectively
functionalized using opportune alkylating agents to give intermediates 6a,b in high purity and
yield [26,31]. Subsequent palladium mediated hydrogenation of 6a,b afforded the corresponding
amino derivatives as free bases, which were immediately converted to hydrochloride salts, since the
compounds are unstable as free bases, to yield derivatives 7a,b. Compounds 7a,b were regioselectively
coupled with the commercially available 4,6-dichloro-2-methylpyrimidine at 50 ◦C in the presence of
N,N-diisopropylethylamine (DIPEA) to afford intermediates 8a,b.
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Scheme 1. Synthesis of final compounds 4a–d and intermediates 9a–c, 10b. Reagents and conditions: 
(a) BrCH2CH2C6H4R1, K2CO3, CH3CN, 60 °C, overnight; (b) H2, Pd/C, EtOH, rt, 2 h, atmospheric 
pressure; (c) HCl in EtOH 2M, rt, 30 min; (d) 4,6-dichloro-2-methylpyrimidine, DIPEA, DMSO, 50 °C, 
overnight; (e) Boc-piperazine or piperazine or 2-(piperazin-1-yl)ethanol, DIPEA, DMSO, 110 °C, 4 h 
under microwave irradiation; (f) methyl bromoacetate, TEA, DMF, rt, 10 min; (g) ammonia 7N in 
MeOH, 100 °C, 3 h, under microwave irradiation. 
The intermediates 8a,b were reacted with the appropriate piperazines at 110 °C under 
microwave irradiation in the presence of DIPEA to afford the final compounds 4a,c and the 
intermediates 9a–c, used for the synthesis of phenol derivatives 4f,i,l described in the Scheme 2. 
Scheme 1. Synthesis of final compounds 4a–d and intermediates 9a–c, 10b. Reagents and conditions:
(a) BrCH2CH2C6H4R1, K2CO3, H3CN, 60 ◦C, overnight; (b) H2, Pd/C, EtOH, rt, 2 h, atmospheric
pressure; (c) HCl in EtOH 2M, rt, 30 min; (d) 4,6-dichloro-2-methylpyr midine, DIPEA, DMSO, 50 ◦C,
overnight; (e) Boc-piperazine or iperazine or 2-( iperazin-1-yl)ethanol, DIPEA, DMSO, 110 ◦C, 4 h
under microwave irrad ation; (f) methyl bromoacetate, TEA, DMF, rt, 10 min; (g) a monia 7N in
MeOH, 100 ◦C, 3 h, under microwave irrad ation.
The intermediates 8a,b ere reacted with the appropriate piperazines at 110 ◦C under microwave
irradiation in the presence of DIPEA to afford the final compounds 4a,c and the intermediates 9a–c,
used for the synthesis of phenol derivatives 4f,i,l described in the Scheme 2. Furthermore, 9a,b were
reacted with methyl bromoacetate to obtain intermediates 10a,b, that were treated with ammonia 7N in
MeOH to yield the final compounds 4b,d, according to the procedure used by Novartis (Scheme 1) [27].
Finally, methoxy derivatives 4a–d, 9a–c, and 10b were treated with sodium methanethiolate in
DMF to obtain the corresponding phenol derivatives 4e–l (Scheme 2).
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2.3. Enzymatic Assays 
Compounds 4a–l have been tested against the isolated Src enzyme and showed IC50 values in 
the nanomolar range. Derivatives 4e–l were found more active on Src than the previous reported hit 
2, showing IC50 values from 93 nM to 40 nM. In particular, compounds 4g, 4j and 4k, bearing a 
hydroxyl group in the ortho or meta positions of the phenyl ring and an amide or methylester 
substituent as side chain, resulted to have the highest inhibitory activity (IC50 values of 40 nM). On 
the other hand, the methoxy derivatives 4a–d are less potent on Src (IC50 values 225–1533 nM) 
compared with the phenolic derivatives, confirming the importance of the hydroxyl group, as 
predicted by modeling studies. In addition, all new compounds were tested for their activity against 
other members of SFKs. As expected, the most promising compounds were also potent inhibitors of 
Yes, Lyn, and Fyn with IC50 values in the range 3–73 nM. These results confirmed the hypothesis that 
the 4-aminoimidazole template, properly decorated, is an effective hinge binder for SFKs and has a 
good/high in vitro potency on these enzymes.  
2.4. Cellular Assays 
Starting from these promising results in enzymatic assays, we decided to test NCEs 4 on K562 
CML and SH-SY5Y NB cell lines, to evaluate if they are endowed with an increased antiproliferative 
activity compared with the hit compound 2. A hyperactivation of SFKs has been detected in both 
K562 and SH-SY5Y cell lines [9,32,33]. Cells were treated with increasing concentrations of 
compounds and cell proliferation was measured by counting viable cells after 72 h of incubation. 
Dasatinib and 2 were used as reference compounds. In Figure 6 we show the activity of 4k and 4l that 
demonstrated, in comparison with the other NCEs (see Supplementary Materials, Figure S1), the best 
antiproliferative activity on SH-SY5Y cells. In detail, 4k and 4l possess IC50 values of 8.6 and 7.8 μM, 
respectively, and show a more than 2-fold increased activity compared to the hit compound 2. 
Importantly, in NB cells, 4k and 4l exerted an antiproliferative effect similar or higher than dasatinib. 
The activity of these compounds could be due not only to Src inhibition, but also to their effect on 
Fyn and Lyn, both involved in NB development [34]. Furthermore, both the compounds showed a 
similar activity on K562 cells, with an antiproliferative effect comparable with the one observed on 
NB cells. In fact, compounds 4k and 4l show IC50 values of 11.7 and 18.9 μM, respectively, and are 
more active than 2, but less active than dasatinib (Figure 6).  
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2.3. Enzymatic Assays
Co pounds 4a–l have been tested against the isolated Src enzyme and showed IC50 values in the
nanomolar range. Derivatives 4e–l were found more active on Src than the previous reported hit 2,
showing IC50 values from 93 nM to 40 nM. In particular, compounds 4g, 4j and 4k, bearing a hydroxyl
group in the ortho or meta positions of the phenyl ring and an amide or methylester substituent as
side chain, resulted to have the highest inhibitory activity (IC50 values of 40 nM). On the other hand,
the methoxy derivatives 4a–d are less potent on Src (IC50 values 225–1533 nM) compared with the
phenolic derivatives, confirming the importance of the hydroxyl group, as predicted by modeling
studies. In addition, all new compounds were tested for their activity against other members of SFKs.
As expected, the most promising compounds were also potent inhibitors of Yes, Lyn, and Fyn with
IC50 values in the range 3–73 nM. These results confirmed the hypothesis that the 4-aminoimidazole
template, properly decorated, is an effective hinge binder for SFKs and has a good/high in vitro
potency on these enzymes.
2.4. Cellular Assays
Starting from these promising results in enzymatic assays, we decided to test NCEs 4 on K562
CML and SH-SY5Y NB cell lines, to evaluate if they are endowed with an increased antiproliferative
activity compared with the hit compound 2. A hyperactivation of SFKs has been detected in both K562
and SH-SY5Y cell lines [9,32,33]. Cells were treated with increasing concentrations of compounds
and cell proliferation was measured by counting viable cells after 72 h of incubation. Dasatinib and 2
were used as reference compounds. In Figure 6 we show the activity of 4k and 4l that demonstrated,
in comparison with the other NCEs (see Supplementary Materials, Figure S1), the best antiproliferative
activity on SH-SY5Y cells. In detail, 4k and 4l possess IC50 values of 8.6 and 7.8 µM, respectively,
and show a more than 2-fold increased activity compared to the hit compound 2. Importantly, in NB
cells, 4k and 4l exerted an antiproliferative effect similar or higher than dasatinib. The activity of
these compounds could be due not only to Src inhibition, but also to their effect on Fyn and Lyn, both
involved in NB development [34]. Furthermore, both the compounds showed a similar activity on
K562 cells, with an antiproliferative effect comparable with the one observed on NB cells. In fact,
compounds 4k and 4l show IC50 values of 11.7 and 18.9 µM, respectively, and are more active than 2,
but less active than dasatinib (Figure 6).
On the basis of the exciting activity of 4k and 4l on NB cell lines in comparison with dasatinib, we
decided to test NCEs also on U87 glioblastoma multiforme (GBM), another tumor characterized by
Src hyperactivation (Figure 6) [35]. Compounds 4k and 4l showed IC50s of 12.6 and 13.3, respectively,
but, unfortunately, resulted less active than dasatinib. A possible explanation could be the multidrug
resistance mechanisms that GBM cells usually carry: an example is the overexpression of membrane
channels (ABCB1) that are able to pump different kind of drugs out of the cells [36]. In Supplementary
Materials, Figure S1, the activity of other NCEs on U87 GBM cell line are reported.
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Figure 6. Antiproliferative effect of 4k and 4l evaluated by in vitro analysis of percentage of viable
cells after 72 h of incubation with SH-SY5Y, K562, and U87 cells. Dasatinib was used as reference
compound. Antiproliferative activity of compound 2 in SH-SY5Y and K562 cells has been also reported.
Percentage was calculated respect to the number of cells treated with the vehicle (100%, bar not shown
in the graph).
In conclusion, a small library of aminoimidazole derivatives was synthesized and screened in a
cell-free assay for their SFK inhibitory activity. Enzymatic assays showed an increase in potency against
isolated Src (from a micromolar range of our previously reported compounds [13] to nanomolar of the
new molecules), with an exceptional increase in potency also against other SFK members. Furthermore,
the most active inhibitors have been tested on three different cancer cell lines, i.e., NB, GBM, and CML
cell lines. Interestingly, compounds 4k and 4l showed good antiproliferative activity in the SH-SY5Y
NB cell line. In this assay the compounds resulted more potent than dasatinib, a TKI inhibitor which is
currently in clinical trials for NB [17].
Further studies on this class of compounds will be focused on the improvement of the ADME
properties, with the aim of obtaining more potent compounds in cell assays.
3. Materials and Methods
3.1. Computational Studies
3.1.1. Protein Preparation
Crystal structures of c-Src in complex with dasatinib and CGP77675 (PDB IDs:3G5D [28] and
1YOL [30]), were retrieved from the RCSB Protein Data Bank. After removal of bound ligands,
the proteins were prepared by using the Protein Preparation Wizard [37] workflow (Schrodinger
Suite). In particular, all water molecules were deleted, hydrogen atoms were added, and partial
charges assigned. In addition, the ionization and tautomeric states of His, Asp, Glu, Arg, and Lys
were adjusted to match pH 7.4. Next, optimization of the hydrogen bonding network was obtained
by reorienting hydroxyl and thiol groups, amide groups of Asn and Gln, and the His imidazole ring.
Finally, the systems were refined by running a restrained minimization (OPLS3 force field) which was
stopped when the RMSD of heavy ato s reached 0.30 Å, the default limit.
3.1.2. Ligands Preparation
Dasatinib, CGP77675 and all our NCEs were drawn and minimized using Maestro 11
(Schrödinger, LLC, New York, NY, USA) and MacroModel (Schrödinger, LLC, New York, NY, USA)
(Schrodinger Suite), respectively. Furthermore, LigPrep (Schrödinger, LLC, New York, NY, USA) was
used to predict ionization and tautomeric states for the ligands using pH 7 ± 0.4.
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3.1.3. Molecular Docking
Docking simulations were performed using the Glide program (Schrödinger, LLC, New York,
NY, USA) [38,39] within the ATP binding site of Src (3G5D). A grid box of default size was centered on
the X-ray ligand. No constraints were included during grid generation while rotation of the hydroxyl
groups was allowed only for those residues closer to the ligand. After grid preparation, NCEs were
flexibly docked and scored using the Glide standard-precision (SP) mode, treating the proteins as rigid.
Docking experiments were performed using 0.80 factor to scale vdW radii of the nonpolar ligand
atoms with a partial atomic charge of <0.15.
3.2. Chemistry
3.2.1. General Information
Reagents used in the following examples were commercially available from various suppliers
(for example Sigma-Aldrich (Milan, Italy), Fluorochem (Hadfield, UK) or Apollo Scientific (Bredbury
Stockport, UK)) and used without further purification. Anhydrous reactions were run under a positive
pressure of dry N2.
1H NMR spectra and 13C NMR were recorded on Bruker 400 MHz NMR spectrometer (Milan,
Italy) using deuterated DMSO (DMSO-d6). Chemical shifts are reported in ppm (δ) using the residual
solvent as the internal standard. Splitting patterns describe apparent multiplicities and are designated
as s (singlet), d (doublet), dd (doublet of doublets), t (triplet), m (multiplet), and br s (broad singlet).
IR spectra were recorded on Perkin Elmer Spectrum 100 FT-IR spectrometer (Milan, Italy).
The accurate masses were measured by the LTQ-Orbitrap XL (Thermo Scientific, Bremen,
Germany) mass spectrometer interfaced with an electrospray ionization (ESI) (Thermo Fisher Scientific,
Waltham, MA, USA) source characterized by spray voltage 4.5 kV, nitrogen as sheath gas (10 a.u).
The resolution of accurate masses is 30,000. MS/MS spectra were recorded with an isolation windows
of 2 mass units, collision energy of 15, 16 or 17 V and Helium as collision gas. UPLC spectra were
performed on a Waters Acquity UPLC-SQD (Waters, Milford, MA, USA) instrument using an Acquity
UPLC-BEH C18 column (1.7 µM, 50 × 2.1 mm) eluting with a gradient mixture of H2O + 0.1% formic
acid-acetonitrile + 0.1% formic acid or ammonium bicarbonate 10 mM (pH = 9) and acetonitrile.
Flash silica gel chromatography was performed on Biotage automatic flash chromatography
systems (Uppsala, Sweden) (Isolera or SP1) using Biotage SNAP HP silica cartridges or Biotage SNAP
KP-NH cartridges. Reverse phase chromatography was performed on a Biotage automatic flash
chromatography system (Isolera) using Redisep Gold C-18Aq cartridges. Purification was also done
by SPE with SCX cartridges. Reactions were monitored by thin-layer chromatography on 0.25 mm
E. Merck silica gel plates (60F-254), visualized with UV light. Melting points (Mp) were determined
with a Büchi B-540 apparatus.
Microwave irradiation experiments were conducted on a Biotage Initiator microwave reactor.
3.2.2. General Procedure for the Synthesis of 1-(2-Phenethyl)-4-nitro-1H-imidazole Derivatives 6a,b
The opportune alkyl bromide (916 mg, 4.26 mmol) was added to a solution of 4-nitro-1H-imidazole
5 (438 mg, 3.87 mmol) in acetonitrile (3 mL) and potassium carbonate (803 mg, 5.81 mmol).
The resulting mixture was heated at 60 ◦C overnight. The reaction mixture was then filtered, and
the filtrate was concentrated in vacuum, leaving a yellow solid. The desired product was recovered
from this residue by normal phase column chromatography on a cartridge Biotage HP-SiO2 (50 g)
column primed with DCM only. The column was then run for 4CV with DCM and then changed to
DCM/MeOH 9:1 over 5CV.
1-[2-(2-Methoxyphenyl)ethyl]-4-nitro-1H-imidazole (6a): White solid, 82% yield, mp: 100–102 ◦C; IR:
ν = 1338 (NO) cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 3.11 (t, J = 7.34 Hz, 2H), 3.75 (s, 3H), 4.28
(t, J = 7.34 Hz, 2H), 6.84 (t, J = 7.34 Hz, 1H) 6.93–7.06 (m, 2H), 7.19–7.26 (m, 1H), 7.67 (s, 1H), 8.30 (s,
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1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 158.8, 146.2, 138.7, 129.9, 128.4, 126.8, 121.5, 120.4, 112.9,
56.8, 49.6, 28.6; HRMS (ESI): m/z calcd. for C12H13N3O3 248.9567 [M + H]+, found 248.9542.
1-[2-(3-Methoxyphenyl)ethyl]-4-nitro-1H-imidazole (6b): Pale yellow solid, 91% yield, mp: 95–97 ◦C; IR:
ν = 1339 (NO) cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 3.08 (t, J = 7.34 Hz, 2H), 3.72 (s, 3H),
4.33 (t, J = 7.34 Hz, 2H), 6.69–6.82 (m, 3H), 7.20 (m, 1H), 7.74 (s, 1H), 8.38 (s, 1H); 13C NMR (100 MHz,
DMSO-d6) δ = ppm 159.5, 146.2, 140.7, 138.7, 129.1, 121.4, 120.4, 115.4, 112.6, 56.0, 49.5, 33.8; HRMS
(ESI) m/z calcd. for C12H13N3O3 248.9567 [M + H]+, found 248.9588.
3.2.3. General Procedure for the Synthesis of 1-(2-Phenylethyl)-1H-imidazol-4-amines 7a,b
1-(2-Phenethyl)-4-nitro-1H-imidazole derivatives 6a,b (544 mg, 2.2 mmol) were dissolved in EtOH
and Pd/C (10 wt %, 96 mg, 0.09 mmol) was added. The mixture was subjected to hydrogenation at
atmospheric pressure for 2 h at room temperature. The mixture was filtered to remove the catalyst and
then an excess of 1.25 M HCl in EtOH was added. The resulting solution was stirred for 30min and
concentrated under reduced pressure to give compounds 7a,b.
1-[2-(2-Methoxyphenyl)ethyl]-1H-imidazol-4-amine hydrochloride (7a): Yellow oil, quantitative yield;
1H NMR (400 MHz, DMSO-d6) δ = ppm 3.04 (t, J = 7.09 Hz, 2H), 3.78 (s, 3H), 4.22 (t, J = 7.09 Hz,
2H), 6.58 (s, 1H), 6.85 (t, J = 7.58 Hz, 1H) 6.96–7.07 (m, 2H), 7.24 (t, J = 7.82 Hz, 1H) 8.30 (s, 1H), (2H
under the solvent residual peak); 13C NMR (100 MHz, DMSO-d6) δ = ppm 158.8, 137.3, 129.9, 128.4,
126.8, 121.5, 112.9, 101.4, 56.8, 49.6, 28.6; HRMS (ESI) m/z calcd. for C12H16ClN3O 218.1215. [M + H]+,
found 218.1235.
1-[2-(3-Methoxyphenyl)ethyl]-1H-imidazol-4-amine hydrochloride (7b): Red oil, quantitative yield; 1H NMR
(400 MHz, DMSO-d6) δ = ppm 3.05 (t, J = 7.09 Hz, 2H), 3.73 (s, 3H), 4.27 (t, J = 7.09 Hz, 2H), 6.64 (s,
1H), 6.73–6.84 (m, 3H), 7.21 (t, J = 7.58 Hz, 1H), 8.33 (s, 1 H), (2H under the solvent residual peak); 13C
NMR (100 MHz, DMSO-d6) δ = ppm 159.5, 140.7, 137.3, 129.1, 121.4, 115.4, 112.6, 101.4, 56.0, 49.5, 33.8;
HRMS (ESI) m/z calcd. for C12H16ClN3O 218.1215 [M + H]+, found 218.1243.
3.2.4. General Procedure for the Synthesis of 6-Chloro-2-methyl-N-[1-(2-phenylethyl)-1H-imidazol-4-
yl]pyrimidin-4-amines 8a,b
Intermediates 7a,b (561 mg, 2.21 mmol) were dissolved in dry DMSO (9 mL). Then 4,6-dichloro-
2-methylpyrimidine (396 mg, 2.43 mmol) and DIPEA (1.54 mL, 8.84 mmol) were added and the
mixture was heated at 50 ◦C overnight. Once the reaction was determined to be complete, DIPEA was
evaporated, AcOH (1 mL) was added and the resulting solution was loaded on RediSep C18Aq column
(150 g) primed with water + 0.1% AcOH. The column was then eluted with 3CV of water + 0.1% AcOH
and then the eluent was gradually changed to acetonitrile + 0.1% AcOH over 12CV.
6-Chloro-N-{1-[2-(2-methoxyphenyl)ethyl]-1H-imidazol-4-yl}-2-methylpyrimidin-4-amine (8a): Purple solid,
55% yield, mp: 135–137 ◦C; IR: ν = 3273 (NH) cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.43 (s,
3H), 3.01 (t, J = 7.09 Hz, 2H), 3.80 (s, 3H), 4.15 (t, J = 7.09 Hz, 2H), 6.69 (br s, 1H), 6.84 (t, J = 7.34 Hz,
1H), 6.99 (d, J = 8.31 Hz, 1H), 7.07 (dd, J = 7.58, 1.71 Hz, 2H), 7.20–7.25 (m, 1H), 7.34 (s, 1H), 10.00 (br
s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 169.7, 158.8, 158.2, 158.1, 154.7, 139.1, 129.9, 128.4,
126.8, 121.5, 112.9, 110.9, 102.7, 56.8, 49.6, 28.6, 25.4; HRMS (ESI) m/z calcd. for C17H18ClN5O 344.1979
[M + H]+, found 344.1991.
6-Chloro-N-{1-[2-(3-methoxyphenyl)ethyl]-1H-imidazol-4-yl}-2-methylpyrimidin-4-amine (8b): Purple solid,
57% yield, mp: 137–140 ◦C; IR: ν = 3273 (NH) cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.43 (s,
3H), 3.02 (t, J = 7.09 Hz, 2H), 3.71 (s, 3H), 4.21 (t, J = 7.09 Hz, 2H), 6.73 (br s, 1H), 6.75–6.82 (m, 4H), 7.20
(t, J = 8.31 Hz, 1H), 7.38 (s, 1H), 10.00 (br s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 169.8, 159.5,
158.2, 158.1, 154.6, 140.7, 139.1, 129.1, 121.4, 115.4, 112.6, 110.9, 102.6, 56.0, 49.5, 33.8, 25.4; HRMS (ESI)
m/z calcd. for C17H18ClN5O 344.1979 [M + H]+, found 344.1995.
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3.2.5. General Procedure for the Synthesis of 2-Methyl-N-[1-(2-phenylethyl)-1H-imidazol-4-yl]-6-
piperazin-1-ylpyrimidin-4-amines 4a,c and 9a–c
The opportune piperazine (0.73 mmol) and DIPEA (0.10 mL, 0.58 mmol) were added to a solution
of the appropriate 6-chloro-2-methyl-N-[1-(2-phenylethyl)-1H-imidazol-4-yl]pyrimidin-4-amine 8a,b
(100 mg, 0.29 mmol) in DMSO (3 mL). The resulting mixture was heated at 110 ◦C for 4 h under
microwave irradiation. The solution in DMSO was acidified with AcOH (0.5 mL) and then loaded on
RediSep C18aq column (50 g) column primed with water + 0.1% AcOH.
To obtain compounds 4a,c and 9c the column was eluted with 2CV of water + 0.1% AcOH and
then the eluent was gradually changed to acetonitrile + 0.1% AcOH over 13CV. The fractions were
combined and evaporated. The orange-brown residue was dissolved in DCM and treated with a
saturated solution of sodium bicarbonate to avoid the acetic acid salt formation. Finally, the organic
phase was dried, filtered and evaporated under vacuum affording the desired compounds.
To obtain compounds 9a,b, the column was eluted with 3CV of water + 0.1% AcOH and then the
eluent was gradually changed to acetonitrile + 0.1% AcOH over 13CV. The fractions containing the
desired product were combined and evaporated to obtain a brown residue. It was dissolved in MeOH
and loaded onto a SPE-SCX (5 g) eluted first with methanol and then with ammonia in methanol (2N).
Basic fractions were collected and evaporated affording the desired compounds.
2-{4-[6-({1-[2-(3-Methoxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-yl}ethanol
(4a): Glassy yellow residue, 65% yield; IR: ν = 3600–2825 (NH + OH) cm−1; 1H NMR (400 MHz,
DMSO-d6) δ = ppm 2.27 (s, 3H), 2.39–2.47 (m, 6H), 3.01 (t, J = 7.09 Hz, 2H), 3.41–3.43 (m, 4H), 3.55 (t,
J = 7.09 Hz, 2H), 3.71 (s, 3H), 4.17 (t, J = 7.34 Hz, 2H), 4.40 (t, J = 5.38 Hz, 1H), 5.94 (s, 1H), 6.75–6.83 (m,
3H), 7.12–7.23 (m, 2H), 7.28 (s, 1H), 8.89 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 168.9, 159.5,
158.4, 157.3, 154.7, 140.7, 139.1, 129.1, 121.4, 115.4, 112.6, 110.9, 89.5, 59.3, 58.0, 56.0, 52.2, 49.5, 47.5, 33.8,
25.4; HRMS (ESI) m/z calcd. for C23H31N7O2 438.2539 [M + H]+, found 438.2572.
2-{4-[6-({1-[2-(2-Methoxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-yl}ethanol
(4c): Glassy yellow residue, 57% yield; IR: ν = 3590–2820 (NH + OH) cm−1; 1H NMR (400 MHz,
DMSO-d6) δ = ppm 2.27 (s, 3H), 2.40–2.47 (m, 6H), 3.00 (t, J = 7.09 Hz, 2H), 3.38–3.44 (m, 4H), 3.53 (t,
J = 7.09 Hz, 2H), 3.81 (s, 3H), 4.11 (t, J = 7.34 Hz, 2H), 4.40 (t, J = 5.38 Hz, 1H), 5.93 (s, 1H), 6.81–6.86 (m,
1H), 6.98 (d, J = 7.83 Hz, 1H), 7.05–7.12 (m, 2H), 7.19–7.26 (m, 2H), 8.88 (s, 1H); 13C NMR (100 MHz,
DMSO-d6) δ = ppm 168.9, 158.8, 158.4, 157.3, 154.7, 139.1, 129.9, 128.4, 126.8, 121.5, 112.9, 110.9, 89.5,
59.3, 58.0, 56.8, 52.2, 49.6, 47.5, 28.6, 25.4; HRMS (ESI) m/z calcd. for C23H31N7O2 438.2539 [M + H]+,
found 438.2525.
N-{1-[2-(2-Methoxyphenyl)ethyl]-1H-imidazol-4-yl}-2-methyl-6-piperazin-1-ylpyrimidin-4-amine (9a): Yellow
oil, 72% yield; IR: ν = 3200 (NH) cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.27 (s, 3H), 2.71–2.73
(m, 4H), 3.00 (t, J = 7.09 Hz, 2H), 3.81 (s, 3H), 4.11 (t, J = 7.09 Hz, 2H), 5.91 (br s, 1H), 6.85 (d, J = 7.34 Hz,
1H), 6.99 (d, J = 8.31 Hz, 1H), 7.05–7.13 (m, 2H), 7.19–7.27 (m, 2H), 8.85 (br s, 1H), (5H under the
solvent residual peak); 13C NMR (100 MHz, DMSO-d6) δ = ppm 168.9, 158.8, 158.4, 157.3, 154.7, 139.1,
129.9, 128.4, 126.8, 121.5, 112.9, 110.9, 89.5, 56.8, 49.6, 48.1, 44.9, 28.6, 25.4; HRMS (ESI) m/z calcd. for
C21H27N7O 394.2271 [M + H]+, found 394.2284.
N-{1-[2-(3-Methoxyphenyl)ethyl]-1H-imidazol-4-yl}-2-methyl-6-piperazin-1-ylpyrimidin-4-amine (9b): Yellow
oil, 80% yield; IR: ν = 3210 (NH) cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.27 (s, 3H), 2.71–2.73
(m, 4H), 3.00 (t, J = 7.09 Hz, 2H), 3.32–3.35 (m, 4H), 3.71 (s, 3H), 4.17 (t, J = 7.09 Hz, 2H), 5.92 (s, 1H),
6.77–6.79 (m, 3H), 7.11–7.23 (m, 2H), 7.28 (s, 1H), 8.86 (br s, 1H), (1H under the solvent residual peak).
13C NMR (100 MHz, DMSO-d6) δ = ppm 168.9, 159.5, 158.4, 157.3, 154.7, 140.7, 139.1, 129.1, 121.4, 115.4,
112.6, 110.9, 89.5, 56.0, 49.5, 48.1, 44.9, 33.8, 25.4. HRMS (ESI) m/z calcd. for C21H27N7O 394.2271
[M + H]+, found 394.2291.
tert-Butyl4-[6-({1-[2-(3-methoxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazine-1-
carboxylate (9c): Pink solid, 28% yield, mp: 145–147 ◦C; IR: ν = 3600 (NH) cm−1; 1H NMR (400 MHz,
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DMSO-d6) δ = ppm 1.43 (s, 9H), 2.29 (s, 3H), 2.94 (t, J = 7.09 Hz, 2H), 3.36–3.46 (m, 8H), 3.73 (s, 3H), 4.14
(t, J = 7.09 Hz, 2H), 5.95 (s, 1H), 6.60–6.65 (m, 3H), 7.05–7.09 (m, 1H), 7.14 (s, 1H), 7.29 (d, J = 1.47 Hz,
1H), 9.27 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 168.99, 159.4, 158.3, 157.3, 155.1, 154.6, 140.7,
139.1, 129.1, 121.4, 115.4, 112.6, 110.9, 89.5, 80.9, 56.0, 49.5, 47.8, 43.6, 33.8, 28.4, 25.4; HRMS (ESI) m/z
calcd. for C26H35N7O3 494.2801 [M + H]+, found 494.2837.
3.2.6. General Procedure for the Synthesis of Methyl [4-(2-methyl-6-{[1-(2-phenylethyl)-1H-imidazol-
4-yl]amino}pyrimidin-4-yl)piperazin-1-yl]acetate Derivatives 10a,b
A mixture of the opportune 2-methyl-N-[1-(2-phenylethyl)-1H-imidazol-4-yl]-6-piperazin-1-
ylpyrimidin-4-amine 9a,b (79 mg, 0.20 mmol), methyl bromoacetate (19 µL, 0.20 mmol), TEA (28 µL,
0.20 mmol) in DMF (1.5 mL) was stirred at room temperature for 10min [27]. DMF was evaporated
under reduced pressure and the crude was loaded onto a Biotage KP-NH (28 g) column primed with
CyHex/AcOEt 1:1. The column was then run for 2CV with CyHex/EtOAc 1:1 and then changed to
AcOEt only for 4CV.
Methyl{4-[6-({1-[2-(2-methoxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-
yl}acetate (10a): Pale yellow residue, 72% yield; IR: ν = 3200 (NH), 1745 (CO) cm−1; 1H NMR (400 MHz,
DMSO-d6) δ = ppm 2.28 (s, 3H), 2.52–2.57 (m, 6H), 3.00 (t, J = 7.09 Hz, 2H), 3.42–3.46 (m, 4H), 3.63 (s,
3H), 3.81 (s, 3H), 4.11 (t, J = 7.09 Hz, 2H), 5.94 (s, 1H), 6.84 (t, J = 7.34 Hz, 1H), 6.99 (d, J = 8.31 Hz, 1H),
7.06–7.13 (m, 2H), 7.20–7.27 (m, 2H), 8.90 (br s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 171.4,
168.9, 158.7, 158.5, 157.3, 154.7, 139.1, 129.9, 128.4, 126.8, 121.5, 112.9, 110.9, 89.5, 60.7, 56.7, 51.8, 51.5,
49.6, 47.5, 28.6, 25.5; HRMS (ESI) m/z calcd. for C24H31N7O3 466.2486 [M + H]+, found 466.2499.
Methyl{4-[6-({1-[2-(3-methoxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-
yl}acetate (10b): Pale yellow residue, 56% yield; IR: ν = 3200 (NH), 1735 (CO) cm−1; 1H NMR (400 MHz,
DMSO-d6) δ = ppm 2.28 (s, 3H), 2.53–2.57 (m, 6H), 3.01 (t, J = 7.09 Hz, 2H), 3.41–3.45 (m, 4H), 3.63 (s,
3H), 3.71 (s, 3H), 4.17 (t, J = 7.09 Hz, 2H), 5.94 (br s, 1H), 6.75–6.84 (m, 3H), 7.12–7.23 (m, 2H), 7.28 (s,
1H), 8.90 (br s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 171.4, 168.9, 159.5, 158.4, 157.3, 154.7,
140.7, 139.1, 129.1, 121.4, 115.4, 112.6, 110.9, 89.5, 60.7, 56.0, 51.8, 51.5, 49.5, 47.5, 33.8, 25.3; HRMS (ESI)
m/z calcd. for C24H31N7O3 466.2486 [M + H]+, found 466.2502.
3.2.7. General Procedure for the Synthesis of 2-[4-(2-Methyl-6-{[1-(2-phenylethyl)-1H-imidazol-4-
yl]amino}pyrimidin-4-yl)piperazin-1-yl]acetamide Derivatives 4b,d
Ammonia 7N in MeOH (10 mL, 70.0 mmol) was added to the opportune methyl [4-(2-methyl-
6-{[1-(2-phenylethyl)-1H-imidazol-4-yl]amino}pyrimidin-4-yl)piperazin-1-yl]acetate derivative 10a,b
(102 mg, 0.22 mmol). The mixture was sealed and heated at 100 ◦C under microwave irradiation for
3 h [27]. The reaction was cooled to room temperature and then solvent was evaporated under reduced
pressure. The crude was dissolved in DMSO and AcOH. The resulting solution was on then loaded on
RediSep C18aq column (50 g) column primed with water + 0.1% AcOH. The column was then eluted
with 3CV of water + 0.1% AcOH and then the eluent was gradually changed to acetonitrile + 0.1%
AcOH over 13CV. The fractions containing the desired product were then combined and evaporated to
obtain a yellow residue. It was dissolved in MeOH and loaded onto a SPE-SCX (2 g), eluted first with
methanol and then with ammonia in MeOH (2N). Basic fractions were collected and evaporated to
obtain desired compounds 4b,d.
2-{4-[6-({1-[2-(3-Methoxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-
yl}acetamide (4b): white solid, 57% yield, mp: 198–200 ◦C; IR: ν = 3260, 3180 (NH2), 1675 (CO)
cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.28 (s, 3H), 2.91 (br s, 2H), 3.01 (t, J = 7.09 Hz, 2H),
3.44–3.48 (m, 4H), 3.71 (s, 3H), 4.17 (t, J = 7.09 Hz, 2H), 5.95 (s, 1H), 6.76–6.81 (m, 3H), 7.09–7.26 (m,
4H), 7.29 (d, J = 1.47 Hz, 1H), 8.91 (br s, 1H), (4H under the solvent residual peak); 13C NMR (100 MHz,
DMSO-d6) δ = ppm 169.2, 168.9, 159.4, 158.4, 157.3, 154.7, 140.7, 139.3, 129.1, 121.4, 115.4, 112.5, 110.9,
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89.5, 60.6, 56.0, 51.5, 49.5, 47.5, 33.8, 25.4; HRMS (ESI) m/z calcd. for C23H30N8O2 451.2488 [M + H]+,
found 451.2510.
2-{4-[6-({1-[2-(2-Methoxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-
yl}acetamide (4d): White solid, 69% yield, mp: 195–198 ◦C; IR: ν = 3260, 3180 (NH2), 1675 (CO)
cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.28 (s, 3H), 2.91 (br s, 2H), 3.01 (t, J = 7.09 Hz, 2H),
3.44–3.48 (m, 4H), 3.71 (s, 3H), 4.17 (t, J = 7.09 Hz, 2H), 5.95 (s, 1H), 6.76–6.81 (m, 2H), 7.09–7.26 (m,
6H), 7.28–7.30 (m, 1H), 8.91 (br s, 1H), (3H under the solvent residual peak); 13C NMR (100 MHz,
DMSO-d6) δ = ppm 169.2, 168.9, 158.7, 158.4, 157.3, 154.7, 139.1, 129.9, 128.4, 126.8, 121.5, 112.9, 110.9,
89.5, 60.5, 56.8, 51.5, 49.6, 47.4, 28.6, 25.4; HRMS (ESI) m/z calcd. for C23H30N8O2 451.2488 [M + H]+,
found 451.2502.
3.2.8. General Procedure for the Synthesis of (2-{4-[(2-Methyl-6-piperazin-1-ylpyrimidin-4-yl)amino]-
1H-imidazol-1-yl}ethyl)phenol Derivatives 4e–l
Sodium methanethiolate (91 mg, 1.30 mmol to obtain compounds 4e–g, 4j–l; 98 mg, 1.40 mmol to
obtain compounds 4h,i) was added to a solution of the appropriate N-{1-[2-(methoxyphenyl)ethyl]-
1H-imidazol-4-yl}-2-methyl-6-piperazin-1-ylpyrimidin-4-amine derivative 4a–d, 9a–c, 10b (0.10 mmol)
in DMF (2 mL). The mixture was bubbled with N2 for 3min and heated at 140 ◦C for 2–6 h under
microwave irradiation. The reaction was cooled to room temperature, AcOH/water (1:1) was added
until pH 5/6 and then the mixture was evaporated to dryness under Rxn RP (2 g) cartridges high
vacuum. The residue obtained was redissolved in DMF and loaded onto PoraPakTM primed with
water + 0.1% AcOH. The column was run with water + 0.1% AcOH for 3CV and then the eluent was
gradually changed to acetonitrile + 0.1% AcOH for 10CV. Fractions containing the desired product
were evaporated to give compounds 4g, j–l. To obtain compounds 4e,f,h,i, the residue was dissolved
in MeOH and loaded onto a SPE-SCX (2 g) eluted first with MeOH and then with ammonia in MeOH
(2N). Basic fractions were collected and evaporated giving the desired compounds.
2-{2-[4-({6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1H-imidazol-1-yl]ethyl}phenol
(4e): Pale yellow solid, 30% yield, mp: 151–153 ◦C; IR: ν = 3500–3250 (2OH, NH) cm−1; 1H NMR
(400 MHz, DMSO-d6) δ = ppm 2.28 (s, 3H), 2.97 (t, J = 7.09 Hz, 2H), 3.35–3.49 (m, 3H), 3.58 (m, 2H),
4.08 (d, J = 5.38 Hz, 1H), 4.12 (t, J = 7.09 Hz, 2H), 4.45 (br s, 1H), 5.97 (br s, 1H), 6.69 (t, J = 7.46 Hz,
1H), 6.80–6.84 (m, 1H), 6.98–7.07 (m, 2H), 7.13 (br s, 1H), 7.29 (d, J = 1.47 Hz, 1H), 8.95 (br s, 1H), 9.46
(s, 1H), (6H under the solvent residual peak); 13C NMR (100 MHz, DMSO-d6) δ = ppm 168.9, 158.4,
157.3, 154.8, 154.7, 139.1, 129.3, 126.7, 124.3, 120.9, 116.7, 110.9, 89.5, 59.3, 58.0, 52.2, 49.6, 47.5, 28.8, 25.4;
HRMS (ESI) m/z calcd. for C22H29N7O2 424.2372 [M + H]+, found 424.2401.
2-(2-{4-[(2-Methyl-6-piperazin-1-ylpyrimidin-4-yl)amino]-1H-imidazol-1-yl}ethyl)phenol (4f): White solid,
24% yield, mp: 193–196 ◦C; IR: ν = 3595–3300 (OH, NH) cm−1; 1H NMR (400 MHz, DMSO-d6)
δ = ppm 2.27 (s, 3H), 2.74–2.79 (m, 4H), 2.94 (t, J = 7.09 Hz, 2H), 3.35–3.40 (m, 4H), 4.14 (t, J = 7.09 Hz,
2H), 5.91–5.95 (m, 1H), 6.66–6.71 (m, 1H), 6.80–6.85 (m, 1H), 6.99–7.07 (m, 2H), 7.12 (s, 1H), 7.28 (s, 1H),
8.86–8.90 (m, 2H), 9.46 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 168.9, 158.4, 157.3, 154.8, 154.7,
139.1, 129.3, 126.7, 124.3, 120.9, 116.7, 110.9, 89.5, 49.6, 48.1, 44.9, 28.8, 25.4; HRMS (ESI) m/z calcd. for
C20H25N7O 380.2020 [M + H]+, found 380.2045.
2-{4-[6-({1-[2-(2-Hydroxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-
yl}acetamide (4g): pale yellow solid, 30% yield, mp: 160–163 ◦C; IR: ν = 3590 (OH), 3520 (NH), 3363
(NH), 1640 (CO) cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.28 (s, 3H), 2.43–2.48 (m, 2H), 2.90
(s, 2H), 2.97 (t, J = 7.34 Hz, 2H), 3.47 (m, 4H), 4.12 (t, J = 7.34 Hz, 2H), 5.95 (s, 1H), 6.69 (s, 1H), 6.82
(d, J = 7.34 Hz, 1H), 6.98–7.07 (m, 2H), 7.12 (br s, 2H), 7.23 (br s, 1H), 7.28 (d, J = 1.47 Hz, 1H), 8.90
(br s, 1H), 9.48 (br s, 1H), (2H under the solvent residual peak); 13C NMR (100 MHz, DMSO-d6)
δ = ppm 169.2, 168.9, 158.4, 157.3, 154.8, 154.7, 139.1, 129.3, 126.7, 124.3, 120.9, 116.7, 110.9, 89.5, 60.6,
51.5, 49.6, 47.4, 28.8, 25.3; HRMS (ESI) m/z calcd. for C22H28N8O2 437.2330 [M + H]+, found 437.2373.
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3-{2-[4-({6-[4-(2-Hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1H-imidazol-1-yl]ethyl}phenol
(4h): White solid, 20% yield, mp: 150–155 ◦C; IR: ν = 3500–3250 (2OH, NH) cm−1; 1H NMR (400 MHz,
DMSO-d6) δ = ppm 2.28 (s, 3H), 2.44–2.48 (m, 4H), 2.94 (t, J = 7.34 Hz, 2H), 3.40–3.43 (m, 4H), 3.50–3.58
(m, 2H), 4.13 (t, J = 7.34 Hz, 2H), 4.41 (br s, 1H), 5.94 (s, 1H), 6.59–6.66 (m, 3H), 7.04–7.10 (m, 1H), 7.14
(s, 1H), 7.29 (d, J = 1.47 Hz, 1H), 8.89 (br s, 1H), 9.26 (s, 1H), (2H under the solvent residual peak);
13C NMR (100 MHz, DMSO-d6) δ = ppm 168.9, 158.4, 157.8, 157.3, 154.7, 140.8, 139.1, 130.3, 120.7, 116.7,
116.2, 110.9, 89.5, 59.3, 58.0, 52.2, 49.5, 47.4, 33.8, 25.5; HRMS (ESI) m/z calcd. for C22H29N7O2 424.2372
[M + H]+, found 424.2411.
3-(2-{4-[(2-Methyl-6-piperazin-1-ylpyrimidin-4-yl)amino]-1H-imidazol-1-yl}ethyl)phenol (4i): Yellow solid,
35% yield, mp: 193–196 ◦C; IR: ν = 3590 (OH), 3363 (NH), 3300 (NH) cm−1; 1H NMR (400 MHz,
DMSO-d6) δ = ppm 2.27 (s, 3H), 2.72–2.76 (m, 4H), 2.94 (t, J = 7.09 Hz, 2H), 3.34–3.38 (m, 4H), 4.13 (t,
J = 7.09 Hz, 2H), 5.92 (s, 1H), 6.59–6.65 (m, 3H), 7.04–7.16 (m, 3H), 7.29 (d, J = 1.47 Hz, 1H), 8.86 (br s,
1H), 9.26 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 168.9, 158.4, 157.8, 157.3, 154.7, 140.8, 139.1,
130.3, 120.7, 116.7, 116.2, 110.9, 89.5, 49.5, 48.1, 44.9, 33.8, 25.3; HRMS (ESI) m/z calcd. for C20H25N7O
380.2021 [M + H]+, found 380.2060.
2-{4-[6-({1-[2-(3-Hydroxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-
yl}acetamide (4j): Glassy yellow residue, 28% yield; IR: ν = 3580 (OH), 3525 (NH), 3363 (NH), 1645
(CO) cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.28 (s, 3H), 2.46–2.49 (m, 2H), 2.90 (s, 2H), 2.94
(t, J = 7.09 Hz, 2H), 3.44–3.49 (m, 4H), 4.14 (t, J = 7.09 Hz, 2H), 5.92–5.96 (m, 1H), 6.59–6.65 (m, 3H),
7.04–7.09 (m, 1H), 7.14 (br s, 2H), 7.22 (br s, 1H), 7.29 (d, J = 1.47 Hz, 1H), 8.89 (br s, 1H), 9.27 (br s, 1H),
(2H under the solvent residual peak); 13C NMR (100 MHz, DMSO-d6) δ = ppm 169.2, 168.9, 158.4,
157.8, 157.3, 154.7, 140.8, 139.1, 130.3, 120.7, 116.7, 116.2, 110.9, 89.5, 60.5, 51.5, 49.5, 47.4, 33.8, 25.4;
HRMS (ESI) m/z calcd. for C22H28N8O2 437.2332 [M + H]+, found 437.2379.
Methyl{4-[6-({1-[2-(3-hydroxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazin-1-
yl}acetate (4k): White solid, 67% yield, mp: 127–130 ◦C; IR: ν = 3590 (OH), 3360 (NH); 1745 (CO)
cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 2.28 (s, 3H), 2.55–2.57 (m, 4H), 2.94 (t, J = 7.34 Hz, 2H),
3.29 (s, 2H), 3.41–3.46 (m, 4H), 3.63 (s, 3H), 4.13 (t, J = 7.34 Hz, 2H), 5.94 (s, 1H), 6.59–6.65 (m, 3H),
7.04–7.09 (m, 1H), 7.14 (s, 1H), 7.29 (d, J = 1.47 Hz, 1H), 8.89 (s, 1H), 9.28 (br s, 1H); 13C NMR (100 MHz,
DMSO-d6) δ = ppm 171.4, 168.9, 158.4, 157.8, 157.3, 154.7, 140.8, 139.1, 130.3, 120.7, 116.7, 116.2, 110.9,
89.5, 60.7, 51.8, 51.5, 49.5, 47.4, 33.8, 25.5; HRMS (ESI) m/z calcd. for C23H29N7O3 452.2332 [M + H]+,
found 452.2359.
tert-Butyl4-[6-({1-[2-(3-hydroxyphenyl)ethyl]-1H-imidazol-4-yl}amino)-2-methylpyrimidin-4-yl]piperazine-1-
carboxylate (4l): pale pink solid, 44% yield, mp: 127–130 ◦C; IR: ν = 3595 (OH), 3363 (NH), 1750 (CO)
cm−1; 1H NMR (400 MHz, DMSO-d6) δ = ppm 1.43 (s, 9H), 2.29 (s, 3H), 2.94 (t, J = 7.09 Hz, 2H),
3.36–3.46 (m, 8H), 4.14 (t, J = 7.09 Hz, 2H), 5.95 (s, 1H), 6.60–6.65 (m, 3H), 7.05–7.09 (m, 1H), 7.14 (s,
1H), 7.29 (d, J = 1.47 Hz, 1H), 8.96 (s, 1H), 9.27 (s, 1H); 13C NMR (100 MHz, DMSO-d6) δ = ppm 168.9,
158.4, 157.8, 157.3, 155.1, 154.7, 140.8, 139.1, 130.3, 120.7, 116.7, 116.2, 110.9, 89.5, 80.9, 49.5, 47.8, 47.8,
43.6, 33.8, 28.5, 28.4, 25.4; HRMS (ESI) m/z calcd. for C25H33N7O3 480.2651 [M + H]+, found 480.2610.
3.3. Enzymatic Assays
Enzymatic assays to determine the kinase inhibitory activity of NCEs were performed
using an automatic liquid-handling device (Microlab STAR Hamilton) and Z’-LYTE Kinase Assay
Platform, a fluorescence resonance energy transfer (FRET)-based assay platform compatible with
high-throughput screening (HTS) applications. The assay has a fluorescence-based, coupled-enzyme
format and uses the differential sensitivities of phosphorylated and non-phosphorylated peptides
toward proteolytic cleavage. The assay procedure was carried out according to the supplier’s
indications. Test compounds were evaluated in a primary screen against active human recombinant
Src (62.3 kDa), followed by a profiling assay toward a selected panel of Src family kinases (Fyn, LynA,
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and Yes1, all human recombinant full-length proteins) according to a procedure already reported.
Final results have been expressed as percent inhibition, and IC50 values were calculated by non-linear
curve fitting using GraphPad Prism software (version 6 for Windows). The inter-experimental
variability of IC50 values resulted within accepted limits of ±0.5 log units.
3.4. Cellular Assays
In vitro experiments were carried out using human neuroblastoma cell line SH-SY5Y, human
glioblastoma cell line U-87, and human erythroleukemia cell line K-562. Cell lines were obtained
from American Tissue Culture Collection (ATCC, SH-SY5Y CRL-2266; U-87 HTB-14; K-562 CCL-243).
K-562 cells were cultured in RPMI medium with 10% FCS. SH-SY5Y and U-87 cells were cultured in
DMEM medium with 10% FCS. In order to determine antiproliferative effect of NCE compounds cells
were seeded at density of 5 × 104 cells/mL (K-562) or 10 × 104 cells/cm2 (SH-SY5Y, U-87) and treated
with increasing concentrations of NCE compounds. Control cells were treated with the vehicle of the
experimental point containing the highest percentage of DMSO. Cell cultures were maintained at 37 ◦C
in 5% v/v CO2 for 72 h. Cell number and vitality were evaluated on cell suspension using the automatic
cell counter NucleoCounter® (Chemometec, Denmark). Results from the NucleoCounter represented
either total or non-viable cell concentration, depending on the sample preparation indicated by the
manufacturer. Each experiment was performed at least three times and results were expressed as mean
and standard deviation.
Supplementary Materials: The following are available online. Figure S1: Antiproliferative effect of selected
compounds evaluated by in vitro analysis of percentage of viable cells respect untreated cells (100%) after 72 h
of incubation. Compounds were used for treating neuroblastoma cells (upper panel) and glioblastoma cells
(bottom panel).
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Abbreviations
ABCB1 ATP-binding cassette sub-family B member 1
ALL acute lymphoblastic leukemia
Bcr-Abl breakpoint cluster region-Abelson
Btk Bruton’s tyrosine kinase
CML chronic myeloid leukemia
c-Src cellular-sarcoma tyrosine kinase
DIPEA N,N-diisopropylethylamine
EMA European Medicines Agency
FDA Food and Drug Admnistration
FRET fluorescence resonance energy transfer
GBM glioblastoma multiforme
HRI hydrophobic region I
HTS high-throughput screening
NB neuroblastoma
NCEs new chemical entities
PDGFR platelet derived growth factor receptor
Ph+ Philadelphia chromosome–positive
RET REarranged during Transfection
SFK Src family kinase
SH Src homology
STK serine/threonine kinase
TK tyrosine kinase
VEGFR vascular endothelial growth factor
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